bio sketch column
At Promega, I am focused on the development and application of target engagement technologies to investigate drug-target interactions in live cells using NanoBRET. I am broadly interested in applying this technology to many target families to enable advanced applications such as of live-cell selectivity profiling and intracellular permeability analyses. Prior to joining the team at Promega, I received my Ph.D. in Biochemistry from the University of Wisconsin, Madison, where I focused on developing inhibitors for the collagen prolyl 4-hydroxylases, a group of enzymes implicated in myriad diseases including fibrosis, scurvy, and cancer. I received my Bachelor of Science in Biochemistry from Lafayette College in Easton, Pennsylvania, where I focused on using analytical methodologies to discover small-molecule biomarkers of parasitic infections.